Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Current Assets (2020 - 2023)

Terns Pharmaceuticals' Current Assets history spans 4 years, with the latest figure at $270.5 million for Q3 2023.

  • For Q3 2023, Current Assets rose 41.94% year-over-year to $270.5 million; the TTM value through Sep 2023 reached $270.5 million, up 41.94%, while the annual FY2022 figure was $285.2 million, 70.84% up from the prior year.
  • Current Assets reached $270.5 million in Q3 2023 per TERN's latest filing, down from $288.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $299.7 million in Q1 2023 to a low of $90.9 million in Q4 2020.
  • Average Current Assets over 4 years is $204.4 million, with a median of $188.7 million recorded in 2021.
  • Peak YoY movement for Current Assets: dropped 23.69% in 2022, then surged 102.18% in 2023.
  • A 4-year view of Current Assets shows it stood at $90.9 million in 2020, then skyrocketed by 83.7% to $166.9 million in 2021, then surged by 70.84% to $285.2 million in 2022, then fell by 5.17% to $270.5 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Current Assets are $270.5 million (Q3 2023), $288.3 million (Q2 2023), and $299.7 million (Q1 2023).